<DOC>
	<DOCNO>NCT01923506</DOCNO>
	<brief_summary>This phase I trial study side effect best dose stereotactic body radiation therapy treat patient prostate cancer undergo surgery . Stereotactic body radiation therapy may able send x-ray directly tumor cause less damage normal tissue .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy Treating Patients With Prostate Cancer After Undergoing Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) upper limit 45 Gray ( Gy ) 5 fraction , delivery stereotactic body radiation therapy ( SBRT ) prostate fossa . SECONDARY OBJECTIVES : I . To assess acute late toxicity treatment . II . To assess biochemical progression-free survival . III . To collect prospective quality-of-life data related bowel , urinary , sexual health . OUTLINE : This dose-escalation study . Patients receive 5 fraction SBRT 1.5 week . After completion study treatment , patient follow 90 day periodically 3 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>History diagnosis prostate cancer undergo prostatectomy No evidence regional nodal distant metastasis base compute tomography ( CT ) abdomen pelvis whole body bone scan within 120 day prior study entry ; node le 1.5 cm consider reactive biopsy require ; node 1.5 cm large require undergo biopsy negative prior study registration ; bone scan finding absence blastic lytic lesion correlate CT image also deem nonneoplastic Eastern Cooperative Oncology Group ( ECOG ) performance scale 02 Child bear potential : In patient population , pertain ability conceive child ; eligible patient already receive prostatectomy , therefore risk applicable Prostate specific antigen ( PSA ) value undetectable value 2.0 within 30 day prior study entry PSA value undetectable enrolled pathology prostatectomy demonstrate one following : positive margin , extracapsular extension , seminal vesicle invasion All subject must ability understand willingness sign write informed consent Patients uncontrolled illness include ongoing active infection Patients may receive investigational agent , concurrent biological chemotherapy Patients history prior malignancy ( exception nonmelanoma skin cancer ) ineligible study , unless document diseasefree least 5 year Studyspecific exclusion : History prior radiation pelvis History uncontrolled inflammatory bowel disease Unable comply radiation therapy procedure Subjects , opinion investigator , may able comply safety monitoring requirement study</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>